References
- Strnad V. Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy. Strahlenther Onkol 2004; 180: 710–17. doi: 10.1007/s00066-004-9196-x
- Ferenczi Ö, Major T, Akiyama H, Fröhlich G, Oberna F, Révész M, et al. Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors. Brachytherapy 2021; 20: 376–82. doi: 10.1016/j.brachy.2020.10.008
- Kovács G, Martinez-Monge R, Budrukkar A, Jose Luis G, Bengt J, Vratislav S, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol 2017; 122: 248–54. doi: 10.1016/j.radonc.2016.10.008
- Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 2015; 33: 3269–76. doi: 10.1200/JCO.2015.61.2929
- Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács Gy, Levendag P, Peiffert D, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91: 150–6. doi: 10.1016/j.radonc.2009.01.005
- Ivaldi E, Di Mario D, Paderno A, Piazza C, Bossi P, Nicola Alessandro, et al. Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2, N0-1): A review. Crit Rev Oncol Hematol 2019; 143: 67–75. doi: 10.1016/j.critrevonc.2019.08.003
- Potharaju M, E Raj H, Muthukumaran M, Venkataraman M, IIangovan B, Kupussam S, et al. Long-term outcome of high-dose-rate brachytherapy and perioperative brachytherapy in early mobile tongue cancer. J Contemp Brachytherapy 2018; 10: 64–72. PMID: 29619058
- Aaboubout Y, Van der Toom QM, de Ridder MAJ, Herdt MJ, Van der Steen B, Van Lanschot GC, et al. Is the depth of invasion a marker for elective neck dissection in early oral squamous cell carcinoma? Front Oncol 2021; 11: 628320. doi: 10.3389/fonc.2021.628320
- Sternick ES, editor. The theory and practice of intensity modulated radiation therapy. 1st edition. Madison WI: Advanced Medical Publishing; 1997.
- Grégoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert, Van Gestel D, et al. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 2007; 12: 555–64. doi: 10.1634/theoncologist.12-5-555
- Yu CX, Li XA, Ma L, Chen D, Naqvi S, Shepard D, et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys 2002; 53: 453–63. doi: 10.1016/s0360-3016(02)02777-3
- Osborn J. Is VMAT beneficial for patients undergoing radiotherapy to the head and neck? Radiography 2017; 23: 73–6. doi: 10.1016/j.radi.2016.08.008
- Adler JR, Cox RS. Preliminary experience with CyberKnife - Radiosurgery. Basel: S. Karger; 1996. p. 112–38.
- Kurup G. CyberKnife: a new paradigm in radiotherapy. J Med Phys 2010; 35: 63–4. doi: 10.4103/0971-6203.62194
- Takácsi-Nagy Z, Ferenczi Ö, Major T, Akiyama H, Fröhlich G, Ferenc O, et al. Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1-2 tongue tumours. Strahlenther Onkol 2022; 198: 812–9. doi: 10.1007/s00066-022-01901-w
- Santos M, Guinot JL, Tortajada M, Vendrell JB, López C, La Rosa A, et al. Is perioperative brachytherapy effective in carcinoma of the tongue? J Contemp Brachytherapy 2022; 14: 23–8. doi: 10.5114/jcb.2022.113425
- Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu ICJ, Morris DE, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 641–9. doi: 10.1016/j.ijrobp.2010.08.046
- Yamazaki H, Yoshida K, Yoshioka Y, Shimizutani K, Furukawa S, Koizumi M, et al. High dose rate brachytherapy for oral cancer. J Radiat Res 2013; 54: 1–17. doi: 10.1093/jrr/rrs103
- Union for International Cancer Control, UICC. TNM classification of malignant tumours. 8th Edition. Brierley JD, Gospodarowicz MK, Wittekind C, editors. Wiley Blackwell; 2017.
- Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40: 515–24. doi: 10.1016/s0360-3016(97)00732-3
- ICRU Report 83, Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012; 188: 97–9. doi: 10.1007/s00066-011-0015-x.
- Major T, Fröhlich G, Ágoston P, Polgár Cs, Takácsi-Nagy Z. The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry. Strahlenther Onkol 2022; 198: 93–109. doi: 10.1007/s00066-021-01867-1
- Petera J, Sirák I, Laco J, Kašaová L, Tuček L, Doležalová H, et al. High-dose-rate brachytherapy in early oral cancer with close or positive margins. Brachytherapy 2015; 14: 77–83. doi: 10.1016/j.brachy.2014.08.050
- NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines Version 2.2023, Head and neck cancers. [cited 2023 Apr 15]. Available at:
www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 - Sresty NVNM, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G, et al. Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. Brachytherapy 2010; 9: 235–8. doi: 10.1016/j.brachy.2009.05.006
- Yoshida K, Takenaka T, Akiyama H, Yamazaki H, Yoshida M, Masui K, et al. Three-dimensional image-based high-dose-rate interstitial brachytherapy for mobile tongue cancer. J Radiat Res 2014; 55: 154–61. doi: 10.1093/jrr/rrt079
- Akiyama H, Pesznyák C, Béla D, Ferenczi Ö, Major T, Polgár Cs, et al. Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: a comparative analysis of dosimetry for target volume and organs at risk. Radiol Oncol 2018; 52: 461–7. doi: 10.2478/raon-2018-0042
- Kubota H, Miyawaki D, Mukumoto N, Ishihara T, Matsumura M, Hasegawa T, et al. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma. Radiat Oncol 2021; 16: 1. doi: 10.1186/s13014-020-01701-5
- Peterson DE, Doerr W, Hovan A, Pinto A, Saunders D, Elting LS, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 2010; 18: 1089–98. doi: 10.1007/s00520-010-0898-6
- Swain M, Ghosh-Laskar S. Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: when less is enough. Oral Oncol 2021; 116: 105265. doi: 10.1016/j.oraloncology.2021.105265
- Jánváry ZL, Ferenczi Ö, Takácsi-Nagy Z, Bajcsay A, Polgár Cs, et al. Application of CyberKnife stereotactic radiosurgery in the treatment of head and neck cancer. Magy Onkol 2018; 62: 180–5.
- Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, et al. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer 2020; 20: 730. doi: 10.1186/s12885-020-07231-3
- Kim MS, Malik NH, Chen H, Poon I, Husain Z, Eskander A, et al. Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review. Head and Neck 2022; 44: 770–82. doi: 10.1002/hed.26948
- Zhang Y, Chiu T, Dubas J, Tian Z, Lee P, Gu X, et al. Benchmarking techniques for stereotactic body radiotherapy for early-stage glottic laryngeal cancer: LINAC-based non-coplanar VMAT vs. Cyberknife planning. Radiat Oncol 2019; 14: 193. doi: 10.1186/s13014-019-1404-z
- Owosho AA, Thor M, Oh JH, Riaz N, Tsai CJ, Rosenberg H, et al. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. J Craniomaxillofac Surg 2017; 45: 595–600. doi: 10.1016/j.jcms.2017.01.020